BeOne Medicines (ONC) revenue: $5.3B
BeOne Medicines reported $5.3B of revenue for the year ended Dec 31, 2025, up 40.2% from $3.8B a year earlier.
From BeOne Medicines's filings with the SEC · Read the filing · ONC stock page
BeOne Medicines revenue by year
#667 of 3,623 US companies by revenue · See the full ranking
| Year ended | Revenue | Change |
|---|---|---|
| Dec 31, 2025 | $5.3B | +40% |
| Dec 31, 2024 | $3.8B | +55% |
| Dec 31, 2023 | $2.5B | +74% |
| Dec 31, 2022 | $1.4B | +20% |
| Dec 31, 2021 | $1.2B | – |
Revenue of similar companies
Companies in the same industry as BeOne Medicines, by SEC industry code, with the closest revenue. Each name opens the same page for that company.
| Company | Revenue, latest year | Year ended |
|---|---|---|
| Organon | $6.2B | Dec 31, 2025 |
| BeOne Medicines | $5.3B | Dec 31, 2025 |
| Elanco Animal Health | $4.7B | Dec 31, 2025 |
| Jazz Pharmaceuticals | $4.3B | Dec 31, 2025 |
| PERRIGO | $4.3B | Dec 31, 2025 |
| Alnylam Pharmaceuticals | $3.7B | Dec 31, 2025 |
| Biomarin Pharmaceutical | $3.2B | Dec 31, 2025 |
Questions and answers
What is BeOne Medicines's revenue?
BeOne Medicines reported $5.3B of revenue for the year ended Dec 31, 2025, up 40.2% from $3.8B a year earlier.
Numbers as reported in BeOne Medicines's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology